topeeng.gif (8416 bytes)

[ Scientific Activities - Actividades Científicas ]

Inflammation & Infection in Acute Coronary Syndromes

Enrique P. Gurfinkel, M.D., Ph.D.

Director, Coronary Unit, Fundación Favaloro
Buenos Aires- Argentina


The mechanisms responsible for the transition from a relatively stable to a clinically unstable situation, are still obscure.
It is accepted that activated macrophages and T lymphocytes through the release of cytokines, adhesive proteins and tissue factor modify the plaque stability
(1- 2- 3).
The fibrous layer becomes thinner and prone to rupture
(4).   The exposure of plaque components to the blood stream triggers the formation of an endoluminal thrombus and the onset of acute coronary events (5).
In fact, during the acute phase of coronary syndromes the coagulation cascade is extremely activated. This pathophisiological process justified the use of antithrombotic therapies
(6).

During the clinical practice, a substantial number of unstable angina patients have an adverse clinical outcome despite the use of aspirin and standard heparin during the acute phase (7). This loss of an initial benefit could be explained by the rebound activation of the coagulation system that follows the discontinuation of the heparin infusion (8- 9) and the continuing inflammatory process that remains up to 6 months from the onset of the coronary event (10). Then it is possible to understand that cyclic waves of thrombosis and lysis may occur preceding clot formation which becomes into ischemic complications.

A sizable proportion of patients with these acute coronary syndromes continue to have a severe adverse events outcomes despite the initial approach during the in-hospital stay. The incidence of the sum of death, and acute myocardial infarction at hospital discharge rose to 8% by two months and 14% by one year.

Then, other potential pathophisiological mechanism could be implicated in the instabiltity of the plaque.
Recently, there has been renewed interest in the possibility that coronary heart disease might be associated with infection and specifically with Chlamydia pneumoniae infection. This organism is now recognised as a common cause of respiratory tract infection. Several investigators have documented an association between coronary heart disease and the presence of high titres of antibodies to C. pneumoniae
(11-12-13). The organism has been detected in atherosclerotic plaques using a variety of techniques including electron microscopy, immunocytochemistry and the polymerase chain reaction (PCR) and viable C. pneumoniae have been cultured from atherosclerotic tissue (14-15). Furthermore, it has recently been found that C. pneumoniae might be involved both in atherogenesis and in the plaque instability (2-16).
In fact, other intracellular pathogens were implicated with atherosclerosis as Cytomegalovirus, Mycoplasma pneumoniae, Helicobacter pylori.
However, there are considerable problems in investigating potential associations between Helicobacter pylori and Coronary Heart Disease
(17).
The impact of Helicobacter pylori infection as an independet risk factor for Coronary Heart Disease seems to be minor
(18).
Patients with Coronary Heart Disease, especially those with two or three vessel diseases, are more often Helicobacter pylory seropositive than the non-diseased controls.
In addition, some studies demonstrated that Helicobacter pylori seropositive is associated with an increase of Acute Myocardial Infarction before statistical adjustment.
But unfortunately, after adjustment for these risk factors, its relation between Helicobacter pylori and Coronary Heart Disease is considerable weak.

Controversial exist as well since Helicobacter pylori seropositivity is inversely related to HDL cholesterol concentrations, but unrelated to other major cardiovascular risk factors (19)
Mycoplasma pneumoniae was also explored in the setting of the acute coronary syndromes but we were unable to find any strong correlation with this pathogen and symptomatic atherosclerosis (20).
Other organisms such as cytomegalovirus have been associated with coronary artery disease, although results have been equivocal and the correlation between these pthogens and coronary artery disease is not as well established as that with C. pneumoniae
(21-22-23).
Therefore, we investigated this infectious process associated with the Human Leukocyte antigens. The HLA system plays an important role in immune response to human diseases and to transplanted organs.
We analyzed the HLA phenotypes in an adequate proportion of patients suffering from unstable angina consecutively selected from Class I and Class II.
What we found was that among HLA DR locus, the B-4 was positively related in patients Chlamydia pneumoniae seropositive who developed major ischemic complications
(24).
Under this circunstances, Chlamydia pneumoniae could modify the adequate inmunological response in this subset of patients.

Then, we decided to test the hypothesis that treatment of patients with unstable angina with and antibiotic with antichlamydial activity, such as roxithromycin, in addition to conventional therapy, might reduce subsequent plaque instability and associated clinical events.
The Roxis Pilot Study
(25) was a double blind, randomized, prospective, multicenter, parallel group, placebo-controlled pilot study with a treatment phase of 30 days and a follow-up period of 6 months.
All patients with non-Q-wave MI and unstable angina that met criteria for type IIIb of Braunwald’s classification received conventional antithrombotic plus antiischemic therapy. When the therapy was started and informed consent was obtained, patients were randomly allocated to receive roxithromycin 150 mg b.i.d. PO or its placebo b.i.d. PO during 30 consecutive days.
The preliminary report showed a rate of recurrent ischemia of 5.4%, myocardial infarction 2.2%, and ischemic death 2.2% in the placebo group, and 1.1%, 0%, and 0% respectively in the roxithromycin group. A statistically significant reduction in the composite double and triple end point rates was observed in favor of the roxithromycin group: (p= 0.04, RR 0.96 [CI 0.92-1.0] and p= 0.009, RR 0.91 [CI 0.85-0.98] respectively). No significant drug related adverse effects were observed.
At 6 months the composite triple end point was 14.6% in the placebo group and 8.69% in the active arm (p value = 0.259)
(26).

The beneficial actions of antibiotics, independent of baseline antibody titres, suggest that IgG titres may not be an adequate marker for guiding treatment therapy (27). Given the relatively small number of events occurring during the study as well as the total sample size, one cannot evaluate if the ischeamic events observed were associated with an acute re-infection, which is common in C pneumoniae, or a chronic infection.
The ROXIS study is one of the first prospective analyses to investigate the prognostic value of c-RP. C-RP levels were not a predictor of primary clinical events, but elevated baseline levels were found in those patients who eventually required a revascularization procedure.

This is consistent with Maseri’s hypothesis (28) that proposes c-RP levels should be included in a patients risk profile. The predictive value, however, might be exaggerated in a low risk population (29), or as in the present study, if one analyses baseline levels during active ischaemia. The relationship between elevated levels of c-RP and the need for revascularization in patients presumably with more diffuse atherosclerotic disease is understandable given that inflammatory cells are found in all stages of chronic atherosclerosis with a potential pathological immune response (30). The immune system is capable of unleashing a powerful inflammatory reaction when stimulated by chlamydia-like bacterial proteins (31), lipopolysaccharides (32), as well as antigens such as heat shock proteins that trigger a humoral and cellular immune reaction (33 -34).
If indeed c-RP is a sensitive but non-specific marker of inflammation, then antibiotics apparently do have an influence in their level. C-RP levels decreased in both groups after the treatment period, although with a significantly greater decrease in the active treatment arm. A potential anti-inflammatory effect of macrolide antibiotics beyond their bactericidal action
(35) remains uncertain and may require different markers of inflammation to evaluate.

Top

References

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-808.
2. Gerrity RG. The role of the monocyte in atherogenesis. Am J Pathol 1981; 103: 181-190.
3. Mazzone A, De Servi S, Ricvutti G, et al. Increase expression of neutrophile and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993; 88: 358-360.
4. van der Wal AC, Becker A, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 90: 1662-1668.
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The patogenesis of the coronary artery disease and the acute coronary syndromes: Part 1 and 2. N Engl J Med 1992; 326: 242-250, 310-318.
6. Gurfinkel E. on Behalf of the Principal Contributors. Current Treatment and Future Prospects for the Management of Acute Coronary Syndromes. Consensus Recomendation of the 1997 Ushuaia Conference. Tierra del Fuego, Argentina. Clin Drug Invest 1998; 15 (5): 368-380.
7. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Circulation 1994; 89:1545-1556.
8. Theroux P, Waters DD, Lam J, Junmau M, McCanse J. Reactivation of unstable angina following discontinuation of heparin. N Engl J Med 1992; 327:141-145.
9. Granger CB, Miller JM, Bovill EG et al : Rebound increase in thrombin generation and activity after cesation of intravenous heparin in patients with acute coronary syndromes.Circulation 1995; 91:1929-1935.
10. Sylven C, Hagerman H, Karlsberg KE et al. Platelet and leukocyte activation after myocardial infarction. E Heart J 1995; 16:1800-1806.
11. Linmammaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993; 87: 1130-1134.
12. Saikku P, Leinonen M, Mattila K. serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; ii: 983-985.
13. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Dalling JR. An association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992 ; 268: 68-72.
14. Muhlstein JB, Hammond EH, Cariquist JF, Radicke E, Thomson MJ, Karagounis JA, Woods ML Anderson JL. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerosis versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27:1555-1561.
15. O’Brien E, Campbell LA, Kuo CC, Stewart D, Benditt E, Grayston JT. Detection of Chlamydia pneumoniae in coronary atherectomy specimens. American College of Cardiology Meeting, Anaheim, California, March 14-18, 1993 (Abstract).
16. Gurfinkel E, Duronto E, Cerda M, Gomez Carretero L, Bozovich G, Rosloznik J, Daroca A, Mautner B. Patients with unstable angina related with C reactive protein and Chalmydia pneumoniae infection. Eur Heart J 1996 (suppl), 17.
17. Rathbone B,Martin D, Stephens J, Thompson JR, Samani NJ. Helicobacter pylori seropositivity in subjects with acute myocardial infarction. Heart 1996; 76: 308-311
18. Niemela S, Kartunen T, Korhonen T, Laara E, Kartunen R, Ikaheimo M, Kesaniemi YA. Heart 1996; 75: 573-575
19. Scragg RKR, Fraser A. Metcalf PA. Helicbacer pylori seropositivity and cardiovascular risk factors in a multicultural workforce. J Epidemiol Common Health 1996; 50: 578-579
20. Gurfinkel E, Rozlosnik J, Bozovich G, Duronto E, Dos Santos A, Mautner B. IgG Antibodies to Chlamydial and Mycoplasma Infection plus C-Reactive Protein Related to Poor Clinical Outcome in Unstable Angina. Arch Inst Cardiol Mex 1997; 67: 462-468
21. Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection of reestenosis and atherosclerosis: focus on citomegalovirus. Lancet 1996; 348 (suppl I) : S13-S17.
22. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour Ca, Camm AJ, Northfield TC. Association of Helicobacter pylory and Chlamydia pneumoniae infection with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711-714.
23. Liusso G, Caliguri G, Grillo RL, Buffon A, Monaco C, Pasceri DJ, et al. Helicobacter pylori and cytomegalovirus infections are strongly associated with atherosclerosis, but not responsible for the instability of angina. J Am Coll Cardiol 1997; (suppl 1): 760-3.
24. Gurfinkel E, Bozovich G. Chlamydia Pneumoniae, inflammation and the Instability of the Atherosclerotic Plaque. Atherosclerosis 1998; 140 Suppl 1:S31-S35.
25. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, Randomzed trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-407.
26.Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mutner B. Treatment with antibiontic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999; 20: 121-127.
27. Gurfinkel E. Is There Something More Behind the Atherosclerotic Plaque Inflammation?. Hotline Editorial. Eur Heart J 1998; 19: 677-678.
28. Maseri A. Inflammation, Atherosclerosis, and Ischemic Events. Exploring the Hidden Side of the Moon. Editorial. N Engl J Med 1997; 336: 1014-1015.
29. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
30. Van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM, Becker AE. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61: 166-170.
31. Miettinen H, Lehto S, Saikku P, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 1996; 17 (5): 682-688.
32. Linnamaki E, Leinomen M, Mattila K, Valtonen V, Saikku P. Chlamydia pneumoniae. Specific circulating immune complexes in patients with coronary heart disease. Circulation 1993; 87: 1130-1134.
33. Metzler B, Schett G, Kleindienst R. Epitope Specificity of Anti-Heat Shock Protein 65/60 Serum Antibodies in Atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17 (3): 536-541.
34. Schett G, Xu Q, Amberger A. Autoantibodies against Heat Shock Protein 60 Mediate Endothelial Cytotoxicity. J Clin Invest 1995; 96 (6): 2569-2577.
35. Kadota JL. Non antibiotic effects of antibiotics. J Clin Microb Infection 1996 (suppl II) s220-s222.

Enrique P. Gurfinkel, M.D., Ph.D.
Director, Coronary Unit, Fundación Favaloro
Avenida Belgrano 1746 (1093)
Buenos Aires- Argentina
Telephone: 54 11 4378 13557- Fax: 54 11 4805 7225
E-mail: gurfi001@ffinme.edu.ar

 

Top

© CETIFAC
Bioengineering

UNER
Update
10/01/99